Anebulo reports Q3 net loss $1.7M; advancing IV selonabant for pediatric cannabis toxicity

Anebulo Pharmaceuticals, Inc.

Operating expenses $1.9M in Q3 fiscal 2025 vs $1.7M year ago.
Net loss $1.7M ($0.04/share) vs $1.7M ($0.06/share) in prior year.
Cash $13.3M plus $3M loan facility; sufficient for planned operations.
Prioritizing IV selonabant for pediatric CNS depression; Phase 1 SAD study to start Q3 2025.
FDA confirmed unmet need for pediatric cannabis toxicity treatment; collaboration suggested.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.